Susanne C. Gruber

Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.

K. Huber, S. Farhan, J. Wojta, 2013, International journal of cardiology.

Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing

E. Grove, K. Huber, J. Wojta, 2015, Thrombosis and Haemostasis.

Influence of dabigatran on pro-inflammatory cytokines, growth factors and chemokines - Slowing the vicious circle of coagulation and inflammation.

E. Haschke-Becher, U. Hoppe, J. Cadamuro, 2020, Life sciences.

Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation

K. Huber, S. Farhan, J. Wojta, 2010, Thrombosis and Haemostasis.

High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch block occurring during transcatheter aortic valve implantation.

K. Huber, A. Geppert, J. Falkensammer, 2014, Heart rhythm.

Safety and efficacy of pharmacological cardioversion of recent-onset atrial fibrillation: a single-center experience.

J. Wojta, P. Eisenburger, F. Egger, 2016, The American journal of emergency medicine.

Endogenous t‐PA‐antigen is an independent predictor of adverse cardiovascular events and all‐cause death in patients with atrial fibrillation

J. Wojta, M. Freynhofer, K. Huber, 2013, Journal of thrombosis and haemostasis : JTH.

Twenty-four-hour time dependency of clopidogrel effects in patients with acute coronary syndromes: The CiCAD-Study

K. Huber, M. Willheim, F. Egger, 2018, Platelets.